In conclusion, our study provides evidence that baseline HBV loads do not affect the prognosis of HCC patients receiving anti-PD-1 in combination with antiangiogenic therapy, while PD-1 inhibitors do not aggravate HBV reactivation and hepatic impairment in patients given TAF prophylaxis. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.